MCID: UND005
MIFTS: 66

Undifferentiated Pleomorphic Sarcoma

Categories: Bone diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Undifferentiated Pleomorphic Sarcoma

MalaCards integrated aliases for Undifferentiated Pleomorphic Sarcoma:

Name: Undifferentiated Pleomorphic Sarcoma 54 60 6 17
Malignant Fibrous Histiocytoma 54 74
Ups 54 60
Malignant Fibrohistiocytic Tumors 54

Characteristics:

Orphanet epidemiological data:

60
undifferentiated pleomorphic sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (United States); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: any age;

Classifications:

Orphanet: 60  
Rare bone diseases


External Ids:

MESH via Orphanet 46 D051677
ICD10 via Orphanet 35 C49.9
UMLS via Orphanet 75 C0334463
Orphanet 60 ORPHA2023
UMLS 74 C0334463

Summaries for Undifferentiated Pleomorphic Sarcoma

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 2023Disease definitionUndifferentiated pleomorphic sarcoma (UPS) is an aggressive sarcoma of soft tissues or bone that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture and occasional systemic features and is characterized by high local recurrence and significant metastasis.EpidemiologyUPS ranks the 4th most common soft tissue sarcoma with a slight male preponderance. The incidence has been evaluated to be close to 0.8-1 new case per 100000 per year in one European series.Clinical descriptionThe tumor arises most commonly during the sixth and seventh decades of life. The most common sites of involvement include lower extremities (mainly thigh) followed by upper arms, retroperitoneum, viscera, head and neck (in childhood). Primary osseous UPS most commonly occurs in distal femur, proximal tibia, proximal femur and humerus. Patients may present pain, swelling / mass and pathological fractures. In the skin, UPS presents as a relatively painless, rapidly enlarging nodule. Anorexia, malaise, fever and weight loss are present in retroperitoneal and inflammatory forms of UPS. Most UPS recur locally; distant metastases are common (the most frequent is lung). Regional metastases are rare.EtiologyUPS is thought to be derived from a primitive mesenchymal cell capable of differentiating into histiocytes, fibroblasts, myofibroblasts and osteoclasts. The etiology of the tumor remains unknown. Prior radiation therapy is a likely risk factor in some cases.Diagnostic methodsAny tumor mass over 5 cm is suspected to be a sarcoma. Magnetic resonance imaging (MRI) is the imaging method of choice for limbs and shows a high signal on T2 weighted images. Histology of biopsy specimen prior to any treatment is crucial to reach diagnosis and shows pleomorphic spindle cell population with large atypical cells frequently exhibiting numerous irregular mitotic figures, associated regions of hemorrhage and necrosis, associated lymphohistiocytic infiltrate and invasion of dermis. Immunohistochemical staining is negative for S-100, HMB-45, CD34 and cytokeratin which assists in ruling out other soft tissue tumors. Most cases previously diagnosed as malignant fibrous histiocytoma have been reclassified into other histological types of sarcoma.Differential diagnosisWhen occurring in skin, UPS is difficult to differentiate from atypical fibroxanthoma or dermatofibrosarcoma protuberans (see this term). Histological differential diagnoses include leiomyosarcoma, rhabdomyosarcoma, lymphoma, and melanoma (see these terms).Management and treatmentUPS should be referred to an expert/ reference center for primary biopsy, expert pathology review, and multidisciplinary treatment. Immediate surgery of a mass without knowledge of its histological nature is strongly discouraged because it is associated with an increased risk of death due to inappropriate resection and increased risk of relapse. UPS is best treated by wide surgical excision. Sometimes amputation may be necessary to remove the whole lesion. Adjuvant radiotherapy is given for high-grade, large (>5 cm), deep-seated tumors, in limb sparing surgeries and when negative margins are not obtained. For non-operable sarcomas, primary radiation therapy could be an option, but usually doxorubicin containing regimens are preferred options in first-line setting for locally irresectable and/or metastatic lesions. Chemotherapy (CHT) with ifosfamide, trabectedin, dacarbazine, pazopanib have demonstrated efficacy in UPS and are registered and available in most European Union countries.PrognosisA 5-year overall survival rate of 48% has been reported for patients with head and neck tumors versus 77% for patients with tumors arising on the trunk and extremities. The childhood variant appears have better prognosis.Visit the Orphanet disease page for more resources.

MalaCards based summary : Undifferentiated Pleomorphic Sarcoma, also known as malignant fibrous histiocytoma, is related to oligodendroglioma and enchondroma. An important gene associated with Undifferentiated Pleomorphic Sarcoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are HIV Life Cycle and TGF-Beta Pathway. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and skin, and related phenotypes are abnormality of the lower limb and abnormality of the peritoneum

Wikipedia : 77 Undifferentiated pleomorphic sarcoma, previously malignant fibrous histiocytoma, is a type of cancer,... more...

Related Diseases for Undifferentiated Pleomorphic Sarcoma

Diseases related to Undifferentiated Pleomorphic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 4091)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 31.5 IDH1 IDH2 PDGFRA
2 enchondroma 30.7 IDH1 IDH2
3 desmoid tumor 30.5 KIT PDGFRA
4 carcinosarcoma 30.4 KIT KRAS PIK3CA
5 differentiated thyroid carcinoma 30.3 KRAS MET NTRK1
6 thyroid cancer 30.1 KIT KRAS MET NTRK1 PIK3CA
7 gastrointestinal stromal tumor 30.1 KIT KRAS PDGFRA
8 bladder urothelial carcinoma 30.1 IDH1 KIT KRAS PIK3CA
9 intrahepatic cholangiocarcinoma 29.9 IDH1 IDH2 KRAS
10 glioma susceptibility 1 29.8 IDH1 IDH2
11 myelodysplastic syndrome 29.8 IDH1 IDH2 KIT KRAS
12 neurilemmoma 29.7 EZR KIT PDGFRA
13 glioma 29.7 IDH1 IDH2 MET PDGFRA PIK3CA
14 spindle cell hemangioma 29.7 IDH1 IDH2
15 myeloma, multiple 29.7 IDH1 IDH2 KIT KRAS STAT3
16 lung cancer susceptibility 3 29.7 IDH1 KRAS MET PIK3CA STAT3
17 pulmonary vein stenosis 29.6 KIT PDGFRA
18 glioblastoma 29.6 IDH1 IDH2 MET PDGFRA PIK3CA
19 leukemia, acute myeloid 29.5 IDH1 IDH2 KIT KRAS STAT3
20 pancreas adenocarcinoma 29.5 KRAS MET PIK3CA STAT3
21 adenoid cystic carcinoma 29.5 IDH1 KIT KRAS PIK3CA
22 squamous cell carcinoma, head and neck 29.4 IDH2 MET PIK3CA STAT3
23 polycythemia vera 29.4 KIT PDGFRA STAT3
24 essential thrombocythemia 29.4 IDH1 IDH2 STAT3
25 medulloblastoma 29.3 IDH1 NTRK1 PDGFRA PIK3CA STAT3
26 cytogenetically normal acute myeloid leukemia 29.3 IDH1 IDH2
27 glioblastoma multiforme 29.3 IDH1 MET PDGFRA PIK3CA STAT3
28 adenosquamous carcinoma 29.1 KIT KRAS PIK3CA
29 spinal chordoma 29.1 MET PDGFRA PIK3CA
30 intraductal papilloma 29.0 IDH1 IDH2
31 intestinal disease 29.0 KRAS PIK3CA STAT3
32 gastric leiomyosarcoma 29.0 KIT PDGFRA
33 hepatocellular carcinoma 29.0 IDH1 IDH2 KRAS MET MIR152 PIK3CA
34 gastric adenocarcinoma 29.0 KIT KRAS MET PIK3CA STAT3
35 hypereosinophilic syndrome, idiopathic 29.0 KIT PDGFRA
36 gastrointestinal system disease 28.9 KIT KRAS STAT3
37 myeloproliferative neoplasm 28.8 KIT PDGFRA STAT3
38 brain cancer 28.7 IDH1 IDH2 PDGFRA PIK3CA STAT3
39 large intestine cancer 28.6 IDH1 IDH2 KRAS MET PIK3CA STAT3
40 respiratory system cancer 28.5 KRAS MET PIK3CA STAT3
41 cholangiocarcinoma 28.3 IDH1 IDH2 KRAS MET MIR152 PIK3CA
42 diaphyseal medullary stenosis with malignant fibrous histiocytoma 13.0
43 malignant fibrous histiocytoma of bone 12.6
44 ichthyosis tapered fingers midline groove up 12.1
45 kabuki syndrome 1 12.1
46 malignant fibroxanthoma 11.8
47 porphyria, acute intermittent 11.7
48 malignant skin fibrous histiocytoma 11.5
49 mastocytosis, cutaneous 11.4
50 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 11.4

Graphical network of the top 20 diseases related to Undifferentiated Pleomorphic Sarcoma:



Diseases related to Undifferentiated Pleomorphic Sarcoma

Symptoms & Phenotypes for Undifferentiated Pleomorphic Sarcoma

Human phenotypes related to Undifferentiated Pleomorphic Sarcoma:

60 33 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the lower limb 60 33 hallmark (90%) Very frequent (99-80%) HP:0002814
2 abnormality of the peritoneum 60 33 hallmark (90%) Very frequent (99-80%) HP:0002585
3 soft tissue sarcoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0030448
4 fever 60 33 frequent (33%) Frequent (79-30%) HP:0001945
5 abnormality of the musculature 60 33 frequent (33%) Frequent (79-30%) HP:0003011
6 fatigue 60 33 occasional (7.5%) Occasional (29-5%) HP:0012378
7 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
8 anorexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002039
9 abnormality of the upper limb 60 33 occasional (7.5%) Occasional (29-5%) HP:0002817
10 abnormal test result 60 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.17 KIT MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.17 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.17 MET
4 Decreased substrate adherent cell growth GR00193-A-4 9.17 KIT MET NTRK1

MGI Mouse Phenotypes related to Undifferentiated Pleomorphic Sarcoma:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.33 CD74 EZR IDH1 KIT KRAS LMNA
2 immune system MP:0005387 10.26 CD74 EZR IDH1 KIT KRAS LMNA
3 mortality/aging MP:0010768 10.26 CD74 EZR IDH1 KIT KRAS LMNA
4 hematopoietic system MP:0005397 10.19 CD74 EZR IDH1 KIT KRAS LMNA
5 cardiovascular system MP:0005385 10.18 IDH2 KIT KRAS LMNA MET PDGFRA
6 integument MP:0010771 10.11 KIT KRAS LMNA MLANA NTRK1 PDGFRA
7 digestive/alimentary MP:0005381 10.1 EZR KIT KRAS LMNA MET PDGFRA
8 muscle MP:0005369 10.06 KIT KRAS LMNA MET NTRK1 PDGFRA
9 craniofacial MP:0005382 10.04 KIT KRAS LMNA MET PDGFRA STAT3
10 neoplasm MP:0002006 9.98 IDH2 KIT KRAS MET PDGFRA PIK3CA
11 limbs/digits/tail MP:0005371 9.97 KIT KRAS LMNA MET NTRK1 PDGFRA
12 no phenotypic analysis MP:0003012 9.95 KIT KRAS MET MLANA NTRK1 PDGFRA
13 normal MP:0002873 9.91 KIT KRAS LMNA MET NTRK1 PDGFRA
14 pigmentation MP:0001186 9.8 KIT KRAS LMNA MLANA NTRK1 PDGFRA
15 renal/urinary system MP:0005367 9.73 KIT KRAS LMNA MET PDGFRA STAT3
16 respiratory system MP:0005388 9.7 IDH1 KIT KRAS LMNA MET PDGFRA
17 skeleton MP:0005390 9.56 CD74 IDH1 KIT KRAS LMNA PDGFRA
18 vision/eye MP:0005391 9.17 KIT KRAS LMNA MET NTRK1 PIK3CA

Drugs & Therapeutics for Undifferentiated Pleomorphic Sarcoma

Drugs for Undifferentiated Pleomorphic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
5
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
10
Lenograstim Approved, Investigational Phase 3 135968-09-1
11
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
12
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
13
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
14
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
15 Olaratumab Approved, Investigational Phase 3 1024603-93-7
16
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
18 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
23
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
24 Anti-Infective Agents Phase 3,Phase 2,Phase 1
25 Antiviral Agents Phase 3,Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
27 Immunologic Factors Phase 3,Phase 1,Phase 2
28 Etoposide phosphate Phase 3,Phase 2
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Antimitotic Agents Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
33 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
34 Antimetabolites Phase 3,Phase 1,Phase 2
35
Indinavir Approved Phase 2 150378-17-9 5362440
36
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
37
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
38
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
39
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
41
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
42
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 46835353 5284616 6436030
43
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
44
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 70789204 6442177
45
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
46
nivolumab Approved Phase 2,Phase 1 946414-94-4
47
Ipilimumab Approved Phase 2 477202-00-9
48
Pembrolizumab Approved Phase 1, Phase 2,Phase 2 1374853-91-4
49
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
50
Mesna Approved, Investigational Phase 2,Not Applicable 3375-50-6 598

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
6 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
11 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
12 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
13 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
14 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
16 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
20 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
23 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
24 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
25 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
26 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
27 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
28 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
29 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
30 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
31 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
32 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
36 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
37 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
38 Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery Recruiting NCT03307616 Phase 2
39 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
40 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
41 Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
42 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03414229 Phase 2 Epacadostat;Pembrolizumab
43 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
44 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
45 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
46 LN-145 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine Phosphate
47 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
48 Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
49 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
50 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib

Search NIH Clinical Center for Undifferentiated Pleomorphic Sarcoma

Genetic Tests for Undifferentiated Pleomorphic Sarcoma

Anatomical Context for Undifferentiated Pleomorphic Sarcoma

MalaCards organs/tissues related to Undifferentiated Pleomorphic Sarcoma:

42
Brain, Kidney, Skin, Thyroid, T Cells, Pituitary, B Cells

Publications for Undifferentiated Pleomorphic Sarcoma

Articles related to Undifferentiated Pleomorphic Sarcoma:

(show top 50) (show all 1748)
# Title Authors Year
1
Undifferentiated pleomorphic sarcoma in a patient with Cowden syndrome after radiotherapy for breast cancer. ( 30047560 )
2019
2
The first ever reported case of malignant fibrous histiocytoma of the scalp. ( 30168269 )
2019
3
Long-Term Survival after Wide Resection of Malignant Fibrous Histiocytoma of the Chest Wall. ( 30834216 )
2019
4
Radiation-Associated Laryngeal Malignant Fibrous Histiocytoma. ( 31046455 )
2019
5
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. ( 31096717 )
2019
6
Large Undifferentiated Pleomorphic Sarcoma of the Posterior Thigh. ( 30853708 )
2019
7
Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein. ( 30591443 )
2019
8
Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma. ( 30267407 )
2019
9
The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1. ( 30303565 )
2019
10
Recurrent Acute Myocardial Infarction Caused by Intra-cardiac Metastatic Undifferentiated Pleomorphic Sarcoma during Cancer Treatment. ( 29629023 )
2018
11
Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. ( 29731980 )
2018
12
Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )
2018
13
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. ( 30249211 )
2018
14
Giant malignant fibrous histiocytoma of the testis. ( 29484233 )
2018
15
Primary Hepatic Malignant Fibrous Histiocytoma on PET/CT. ( 29485437 )
2018
16
Low-Grade Malignant Fibrous Histiocytoma Originating From the Medial Rectus Muscle. ( 29538190 )
2018
17
Intracranial malignant fibrous histiocytoma. ( 29685317 )
2018
18
Splenic malignant fibrous histiocytoma with concurrent hypertension and epistaxis in an Alaskan malamute dog. ( 30103739 )
2018
19
Treatment of spinal malignant fibrous histiocytoma, a case report and literature review. ( 30527900 )
2018
20
Malignant fibrous histiocytoma: Database review suggests a favorable prognosis in the head and neck. ( 28988458 )
2018
21
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. ( 29220302 )
2018
22
Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. ( 30094896 )
2018
23
Aggressive undifferentiated pleomorphic sarcoma of the stomach involving long-term survival: A case report and literature review. ( 30546898 )
2018
24
The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University. ( 30557163 )
2018
25
Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. ( 30386736 )
2018
26
Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. ( 30281149 )
2018
27
Undifferentiated Pleomorphic Sarcoma Metastatic to the Orbit. ( 30289824 )
2018
28
Recurrent Undifferentiated Pleomorphic Sarcoma in the Left Atrium. ( 30062306 )
2018
29
Undifferentiated Pleomorphic Sarcoma of Liver: Case Report and Review of the Literature. ( 30105111 )
2018
30
A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report. ( 30134855 )
2018
31
A case of undifferentiated pleomorphic sarcoma of the breast with lung and bone metastases. ( 30165321 )
2018
32
Undifferentiated Pleomorphic Sarcoma of Pancreas: A Case Report and Review of the Literature for the Last Updates. ( 29955231 )
2018
33
Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report. ( 29702057 )
2018
34
Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes. ( 29787841 )
2018
35
Undifferentiated pleomorphic sarcoma of the orbital region: a case report. ( 29846420 )
2018
36
Cardiac Undifferentiated Pleomorphic Sarcoma Mimicking Left Atrial Myxoma. ( 29551281 )
2018
37
Undifferentiated pleomorphic sarcoma. ( 29641724 )
2018
38
Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. ( 29359268 )
2018
39
Extended right hepatectomy with inferior vena cava replacement for threatening venous outflow occlusion in a pretreated undifferentiated pleomorphic sarcoma of the liver. ( 29366308 )
2018
40
Primary undifferentiated pleomorphic sarcoma of the thyroid: A case report and review of the literature. ( 29443775 )
2018
41
Radiation-induced undifferentiated pleomorphic sarcoma of the heart: A case report. ( 29305110 )
2018
42
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. ( 29308306 )
2018
43
Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. ( 28891048 )
2018
44
Undifferentiated pleomorphic sarcoma: indolent, tail-like recurrence of a high-grade tumor. ( 28932893 )
2018
45
Radiation therapy for recurrent cardiac undifferentiated pleomorphic sarcoma after three operations. ( 28434140 )
2018
46
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. ( 28552826 )
2017
47
Corrigendum to "Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone" [Hum Pathol 2017;65:239-46]. ( 29146074 )
2017
48
A Squamous Cell Carcinoma and a Malignant Fibrous Histiocytoma Developing in a Patient with a Mature Cystic Teratoma. ( 28203171 )
2017
49
Retrovesical malignant fibrous histiocytoma: a rare tumor. ( 29197849 )
2017
50
Primary Pulmonary Malignant Fibrous Histiocytoma. ( 29404161 )
2017

Variations for Undifferentiated Pleomorphic Sarcoma

ClinVar genetic disease variations for Undifferentiated Pleomorphic Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 RECQL4 NM_004260.3(RECQL4): c.1717C> T (p.Gln573Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome 8, 144514350: 144514350
2 RECQL4 NM_004260.3(RECQL4): c.1717C> T (p.Gln573Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome 8, 145739734: 145739734

Cosmic variations for Undifferentiated Pleomorphic Sarcoma:

9 (show top 50) (show all 232)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM212945 XPO1 soft tissue,lower extremity,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 0
2 COSM44683 TP53 soft tissue,arm,leiomyosarcoma,NS c.652G>A p.V218M 17:7674879-7674879 0
3 COSM45253 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.611A>G p.E204G 17:7674920-7674920 0
4 COSM10654 TP53 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.637C>T p.R213* 17:7674894-7674894 0
5 COSM44732 TP53 soft tissue,bone,leiomyosarcoma,NS c.512A>G p.E171G 17:7675100-7675100 0
6 COSM10648 TP53 soft tissue,NS,rhabdomyosarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 0
7 COSM43632 TP53 soft tissue,bone,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 0
8 COSM44151 TP53 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 0
9 COSM11476 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 0
10 COSM45256 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.871A>C p.K291Q 17:7673749-7673749 0
11 COSM10660 TP53 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 0
12 COSM11073 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 0
13 COSM10672 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.577C>T p.H193Y 17:7674954-7674954 0
14 COSM10725 TP53 soft tissue,NS,rhabdomyosarcoma,pleomorphic c.701A>G p.Y234C 17:7674262-7674262 0
15 COSM43919 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.856G>T p.E286* 17:7673764-7673764 0
16 COSM6897049 TOP1 soft tissue,lower extremity,leiomyosarcoma,NS c.1576G>C p.E526Q 20:41114093-41114093 0
17 COSM6911821 SUFU soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.780G>T p.E260D 10:102597163-102597163 0
18 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 0
19 COSM6945139 RICTOR soft tissue,NS,rhabdomyosarcoma,pleomorphic c.2898-1G>T p.? 5:38952426-38952426 0
20 COSM3399394 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1004T>G p.L335* 13:48367558-48367558 0
21 COSM6964600 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.345C>G p.F115L 13:48342679-48342679 0
22 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 0
23 COSM5564171 PTPRT soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3424C>T p.R1142W 20:42106818-42106818 0
24 COSM6927085 PTPRT soft tissue,lower extremity,leiomyosarcoma,NS c.1201C>T p.R401W 20:42472515-42472515 0
25 COSM6933928 PTPRD soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 0
26 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 0
27 COSM5923 PTEN soft tissue,retroperitoneum,leiomyosarcoma,NS c.1027-7T>C p.? 10:87965280-87965280 0
28 COSM5033 PTEN soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.389G>A p.R130Q 10:87933148-87933148 0
29 COSM5154 PTEN soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.697C>T p.R233* 10:87957915-87957915 0
30 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 0
31 COSM1083818 PIK3CG soft tissue,NS,rhabdomyosarcoma,spindle cell c.2638G>A p.E880K 7:106883041-106883041 0
32 COSM1537052 PIK3CA soft tissue,retroperitoneum,leiomyosarcoma,NS c.1798G>A p.E600K 3:179219622-179219622 0
33 COSM6920563 PIK3CA soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 0
34 COSM36289 PIK3CA soft tissue,retroperitoneum,gastrointestinal stromal tumour,spindle c.3143A>G p.H1048R 3:179234300-179234300 0
35 COSM27375 PIK3CA soft tissue,retroperitoneum,gastrointestinal stromal tumour,spindle c.3103G>A p.A1035T 3:179234260-179234260 0
36 COSM775 PIK3CA soft tissue,retroperitoneum,gastrointestinal stromal tumour,spindle c.3140A>G p.H1047R 3:179234297-179234297 0
37 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 0
38 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 0
39 COSM6955391 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452G>A p.S151N 15:88147347-88147347 0
40 COSM6078150 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1577C>A p.P526Q 15:88032865-88032865 0
41 COSM6964921 NTRK3 soft tissue,NS,rhabdomyosarcoma,spindle cell c.492C>A p.C164* 15:88137534-88137534 0
42 COSM584 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.182A>G p.Q61R 1:114713908-114713908 0
43 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 0
44 COSM580 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.181C>A p.Q61K 1:114713909-114713909 0
45 COSM6911819 NOTCH4 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2738C>G p.S913C 6:32210879-32210879 0
46 COSM48604 NOTCH3 soft tissue,lower extremity,leiomyosarcoma,NS c.2741C>T p.P914L 19:15181627-15181627 0
47 COSM6915774 NKX2-1 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.314G>T p.R105M 14:36519044-36519044 0
48 COSM1745010 MYOD1 soft tissue,NS,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 11:17720147-17720147 0
49 COSM6916495 MTOR soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4799A>G p.E1600G 1:11144721-11144721 0
50 COSM293555 MSH6 soft tissue,lower extremity,leiomyosarcoma,NS c.3991C>T p.R1331* 2:47806641-47806641 0

Expression for Undifferentiated Pleomorphic Sarcoma

Search GEO for disease gene expression data for Undifferentiated Pleomorphic Sarcoma.

Pathways for Undifferentiated Pleomorphic Sarcoma

Pathways related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 IDH1 KIT KRAS LMNA MET PDGFRA
2
Show member pathways
13.46 KIT KRAS MET NTRK1 PDGFRA PIK3CA
3
Show member pathways
13.4 EZR KIT KRAS MET PDGFRA PIK3CA
4
Show member pathways
13.34 KIT KRAS MET NTRK1 PDGFRA STAT3
5
Show member pathways
13.28 KIT KRAS MET PDGFRA PIK3CA STAT3
6
Show member pathways
12.99 KIT KRAS MET NTRK1 PDGFRA
7
Show member pathways
12.93 KIT KRAS MET NTRK1 PDGFRA STAT3
8
Show member pathways
12.92 EZR KIT MET NTRK1 PDGFRA
9
Show member pathways
12.86 KIT KRAS MET NTRK1 PDGFRA PIK3CA
10
Show member pathways
12.85 KIT KRAS MET PDGFRA PIK3CA
11
Show member pathways
12.8 KRAS MET PDGFRA PIK3CA STAT3
12
Show member pathways
12.76 KRAS NTRK1 PDGFRA PIK3CA STAT3
13
Show member pathways
12.72 KIT KRAS NTRK1 PDGFRA PIK3CA STAT3
14 12.66 KIT KRAS MET NTRK1 PDGFRA
15 12.64 KIT KRAS MET NTRK1 PDGFRA PIK3CA
16
Show member pathways
12.62 KIT KRAS MET PDGFRA PIK3CA
17
Show member pathways
12.6 KRAS MET NTRK1 PIK3CA STAT3
18
Show member pathways
12.59 KRAS MET PDGFRA PIK3CA STAT3
19 12.56 EZR KRAS PDGFRA PIK3CA
20
Show member pathways
12.55 KIT KRAS MET NTRK1 PDGFRA PIK3CA
21
Show member pathways
12.52 KRAS PDGFRA PIK3CA STAT3
22
Show member pathways
12.51 KRAS MET PIK3CA STAT3
23 12.49 CD74 KIT MLANA STAT3
24
Show member pathways
12.42 KRAS MET PDGFRA PIK3CA
25
Show member pathways
12.37 KRAS MET PIK3CA STAT3
26
Show member pathways
12.33 KRAS PDGFRA PIK3CA STAT3
27
Show member pathways
12.31 KIT KRAS PDGFRA PIK3CA
28
Show member pathways
12.28 KRAS MET NTRK1 PDGFRA PIK3CA
29
Show member pathways
12.12 KIT KRAS MET NTRK1 PDGFRA
30 12.11 EZR KRAS MET PIK3CA STAT3
31
Show member pathways
12.1 KIT KRAS MET NTRK1 PDGFRA PIK3CA
32
Show member pathways
12.05 EZR PIK3CA STAT3
33 12.03 KRAS PIK3CA STAT3
34
Show member pathways
12.02 KRAS PIK3CA STAT3
35
Show member pathways
12.02 KRAS PDGFRA PIK3CA STAT3
36
Show member pathways
12.01 KRAS PIK3CA STAT3
37
Show member pathways
12.01 KRAS MET PIK3CA STAT3
38 12 KIT MET NTRK1 PDGFRA
39
Show member pathways
11.98 KRAS LMNA MET NTRK1 PDGFRA PIK3CA
40 11.98 EZR KRAS MET MIR152 PDGFRA PIK3CA
41 11.85 KRAS PIK3CA STAT3
42 11.82 KRAS PIK3CA STAT3
43
Show member pathways
11.79 KRAS PIK3CA STAT3
44 11.79 KRAS LMNA MET NTRK1 PDGFRA PIK3CA
45
Show member pathways
11.73 KIT KRAS PIK3CA
46 11.66 EZR KRAS NTRK1 PDGFRA
47
Show member pathways
11.57 NTRK1 PIK3CA STAT3
48
Show member pathways
11.36 MET PIK3CA STAT3
49 11.26 KRAS NTRK1 PDGFRA PIK3CA STAT3
50 11.08 PDGFRA PIK3CA

GO Terms for Undifferentiated Pleomorphic Sarcoma

Cellular components related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 CD74 KIT MET NTRK1 PDGFRA
2 receptor complex GO:0043235 8.92 KIT MET NTRK1 PDGFRA

Biological processes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.97 KIT MET NTRK1 PDGFRA PIK3CA
2 phosphorylation GO:0016310 9.91 KIT MET NTRK1 PDGFRA PIK3CA STAT3
3 positive regulation of gene expression GO:0010628 9.89 EZR KIT KRAS LMNA STAT3
4 cytokine-mediated signaling pathway GO:0019221 9.86 KIT KRAS PIK3CA STAT3
5 MAPK cascade GO:0000165 9.83 KIT KRAS MET PDGFRA
6 peptidyl-tyrosine phosphorylation GO:0018108 9.78 KIT MET NTRK1 PDGFRA
7 negative regulation of neuron apoptotic process GO:0043524 9.77 KRAS NTRK1 PIK3CA
8 positive regulation of protein kinase B signaling GO:0051897 9.76 KIT MET PDGFRA PIK3CA
9 liver development GO:0001889 9.72 KRAS MET PIK3CA
10 female gonad development GO:0008585 9.6 IDH1 PDGFRA
11 2-oxoglutarate metabolic process GO:0006103 9.58 IDH1 IDH2
12 positive regulation of phospholipase C activity GO:0010863 9.58 KIT PDGFRA
13 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.56 KIT MET NTRK1 PDGFRA
14 NADP metabolic process GO:0006739 9.54 IDH1 IDH2
15 negative regulation of apoptotic process GO:0043066 9.54 CD74 NTRK1 STAT3
16 isocitrate metabolic process GO:0006102 9.51 IDH1 IDH2
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.46 CD74 KIT NTRK1 PDGFRA
18 glyoxylate cycle GO:0006097 9.4 IDH1 IDH2
19 positive regulation of MAPK cascade GO:0043410 9.26 CD74 KIT NTRK1 PDGFRA
20 phosphatidylinositol phosphorylation GO:0046854 9.02 PIK3CA
21 phosphatidylinositol-mediated signaling GO:0048015 8.92 EZR NTRK1 PDGFRA PIK3CA

Molecular functions related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.85 IDH1 IDH2 KIT NTRK1 PDGFRA STAT3
2 kinase activity GO:0016301 9.8 KIT MET NTRK1 PDGFRA PIK3CA
3 nucleotide binding GO:0000166 9.73 KIT KRAS MET PDGFRA
4 protein tyrosine kinase activity GO:0004713 9.62 KIT MET NTRK1 PDGFRA
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH1 IDH2
6 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 KIT MET NTRK1 PDGFRA
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.65 PIK3CA

Sources for Undifferentiated Pleomorphic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....